ArQule Gets Early-Stage Cancer Program Back From Daiichi
This article was originally published in The Pink Sheet Daily
Executive Summary
The Japanese pharma has elected to return rights to an early-stage cancer development program to ArQule, but the biotech reassured investors the two companies will continue to move forward on their beleaguered late-stage oncology endeavor.